L-Ascorbic acid sodium salt

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

134-03-2

包装与价格：

包装	价格(元)
10 mM * 1 mL in Water	电议
500mg	电议
1 g	电议
5 g	电议
10 g	电议

产品名称

维生素C钠
Sodium ascorbate
Sodium L-ascorbate
Vitamin C sodium salt

产品介绍

L-Ascorbic acid sodium salt (Sodium ascorbate)，一种电子供体，是一种内源性抗氧化剂。L-Ascorbic acid sodium salt 选择性抑制 Ca_v3.2 通道 (Ca_v3.2 channels)，IC₅₀为 6.5 μM。L-Ascorbic acid sodium salt 还是一种胶原沉积促进剂和弹性生成抑制剂。

生物活性

L-Ascorbic acid sodium salt (Sodium ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid sodium salt selectively inhibitsCa_v3.2 channelswith anIC₅₀of 6.5 μM. L-Ascorbic acid sodium salt is also a collagen deposition enhancer and an elastogenesis inhibitor^[1]^[2]^[3].

IC₅₀& Target

T-type calcium channel

Microbial Metabolite

Human Endogenous Metabolite

体外研究
(In Vitro)

The conditioned medium for B16F10 cells significantly inhibits cell apoptosis induced by L-Ascorbic acid sodium salt (Sodium L-ascorbate) (10 mM), and the effective ingredients in the medium show a relative molecular mass below 5,000^[4].

体内研究
(In Vivo)

Tg rats treated with L-Ascorbic acid sodium salt (Sodium L-ascorbate) show a higher incidence of carcinoma (29.6%), compared to those without L-Ascorbic acid sodium salt (15.4%). Independent of the L-Ascorbic acid sodium salt treatment, transgenic rats exhibit various kinds of malignant tumors in various organs^[5].
After 12 weeks of PEITC-treatment, both simple hyperplasia and papillary or nodular (PN) hyperplasia have developed in all animals, but the majority of these lesions have disappeared at week 48, irrespective of the L-Ascorbic acid sodium salt-treatment. The same lesions after 24 weeks of PEITC-treatment have progressed to dysplasia and carcinoma, in a small number of cases by week 48, but enhancement by the L-Ascorbic acid sodium salt-treatment is evident only with simple hyperplasias and PN hyperplasias in rats^[6].

Clinical Trial

分子量

198.11

性状

Solid

Formula

C₆H₇NaO₆

CAS 号

134-03-2

中文名称

L-抗坏血酸钠；维生素C钠

结构分类

Others

来源

Plants
other families

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

溶解性数据

In Vitro:

H₂O : 100 mg/mL(504.77 mM;Need ultrasonic)

DMSO : 1 mg/mL(5.05 mM;Need ultrasonic)

配制储备液

浓度溶剂体积质量

1 mg

5 mg

10 mg

1 mM	5.0477 mL	25.2385 mL	50.4770 mL
5 mM	1.0095 mL	5.0477 mL	10.0954 mL
10 mM	0.5048 mL	2.5239 mL	5.0477 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture and light)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.
请依序添加每种溶剂： PBS
Solubility: 50 mg/mL (252.39 mM); Clear solution; Need ultrasonic

*以上所有助溶剂都可在本网站选购。